Xiao and colleagues revealed that DLGAP1-AS2, indirectly motivates the AKT/mTOR/cyclinD1 signaling pathway, by regulating E2F1 affecting CD151 expression levels, and causing radiotherapy resistance in CRC cells [117]. Here, DLGAP1 is linked to colorectal carcinoma.